Phase 2a shows that bosutinib, a c-Abl/Src inhibitor, significantly increases dopamine and reduces alpha-synuclein levels and improves activities of daily living in patients with Dementia with Lewy Bodies (DLB) [10,11]. Here, ABL1 is linked to Lewy body dementia.